3 recruiting, 1 not yet recruiting, 1 terminated, 1 unknown. 4 Phase 2, 2 Not applicable, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Recruiting 2, Terminated 1, Unknown 1 |
| Not applicable | 2 | Not yet recruiting 1, Recruiting 1 |
| Phase 3 | 1 | Unknown 1 |
Follow THERABIONIC INC.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of the TheraBionic P1 Device in Patients With Metastatic Triple Negative Breast Cancer After Progression TheraBionic P1 - Triple Negative Breast Cancer | Not applicable | Not yet recruiting | Barbara Ann Karmanos Cancer Institute | 24 | 2026-09-01 | 2026-06-29 |
| TheraBionic P1 Device in Subjects With Advanced Hepatocellular Carcinoma TheraBionic P1 - Hepatocellular Carcinoma Recurrent | Not applicable | Recruiting | Barbara Ann Karmanos Cancer Institute | 198 | 2025-10-20 | 2026-11-12 |
| Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer Fruquintinib, TheraBionic P1 - Metastatic Colorectal Adenocarcinoma | Phase 2 | Recruiting | Barbara Ann Karmanos Cancer Institute | 102 | 2025-09-10 | 2025-11-10 |
| Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma TheraBionic Device, Placebo Device, Quality of Life Assessment - Hepatocellular Carcinoma | Phase 2 / Phase 3 | Unknown | THERABIONIC INC. | 166 | 2023-07-01 | 2023-06-28 |
| Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer Nab paclitaxel, Gemcitabine, TheraBionic - Pancreatic Cancer, Metastatic Adenocarcinoma | Phase 2 | Recruiting | THERABIONIC INC. | 46 | 2023-06-13 | 2025-03-25 |
| Study Of Intrabucally Administered Electromagnetic Fields and Regorafenib TheraBionic, Regorafenib - Hepatocellular Carcinoma | Phase 2 | Terminated | Wake Forest University Health Sciences | 2 | 2021-01-26 | 2026-03-05 |
Carcinoma, Hepatocellular (2) · Adenocarcinoma (1) · Pancreatic Neoplasms (1) · Triple Negative Breast Neoplasms (1)
Gemcitabine (1) · HMPL-013 (1) · Taxes (1) · regorafenib (1)
United States (6)
Ravi Paluri, MD (2) · Anthony F Shields, M.D. (1) · Jailan Elayoubi, M.D. (1) · Mohammed Najeeb Al Hallak, MD (1) · Valerie K Pasche, MD (1)
P30CA012197 (1), R44CA256984 (1)